JP Conte, Managing Partner of Lupine Crest Capital, has long held that permanent capital structures outperform fund-stage sponsors over a full cycle. The fundraising data is now making that case in real time. Global private equity fundraising fell to around $150 billion in Q2 2025, while commitments to traditional commingled funds dropped roughly 24% year over year, per PwC’s 2026 private equity outlook. A closer look at Conte’s reasoning explains where the capital is actually moving and why the shift favors patient capital structures.

US fundraising specifically tracked roughly 40% below the prior year period. The marginal dollar that would have flowed to a mid-market PE fund five years ago is now going elsewhere, and family offices are among the largest recipient categories. PwC describes the dynamic directly: more sponsors are chasing fewer high-quality assets while sovereign wealth funds and family offices expand their footprint on patient capital and lower-debt structures. Large diversified asset managers are also absorbing a growing share of LP commitments, and limited partners are backing fewer firms overall and demanding more demonstrated value creation from the ones they do back.

That LP concentration is self-reinforcing. Sponsors that don’t make the cut for large allocations compete for smaller pools with less capital. Jean-Pierre Conte’s firm doesn’t face that fundraising dynamic because it operates from a permanent capital base with no external LP to satisfy. Bain & Company’s 2026 private equity report describes the current recovery as a narrow one powered by megadeals and flags the vulnerability of any rebound that depends on a small number of very large transactions to keep widening. Patient capital structures are built to perform even when that rebound stalls.

Lupine Crest Capital invests across private equity, real estate, and venture with a middle-market focus on healthcare, financial services, software, and industrial technology. The J-P Conte Family Foundation, established in 2017, extends that long-range philosophy into philanthropy, supporting education, medical research, and conservation. His profile as an experienced allocator in private equity gives Lupine Crest the deal access and seller relationships that fundraising-dependent firms can’t easily match when the capital environment tightens.